+1803294983432
customer.service@microbix.com
Microbix Announces Annual Meeting Voting Results
Microbix announces the voting results from the Annual Meeting of Shareholders of the Company (the “Meeting”) which was held on March 25, 2026.
Microbix Presents Reference-Material Innovations at EUROGIN
Microbix announces that it is presenting results of novel QUANTDx™ reference materials designed to emulate real-life human papillomavirus (“HPV”) patient-samples an…
Microbix’s Clot-Buster Drug Project Advances
Microbix announces that the contract development and manufacturing organization (“CDMO”) engaged by its funding and commercialization partner, Sequel Pharma, LLC (“…
Microbix Announces Issuance of Stock Options
Microbix announces the issuance of stock options under its shareholder-approved stock option plan (the “Stock Option Plan”), as part of its compensation programs to i…
Microbix – KRC Insights FQ1 2026 Update
KRC Insights published an update report on Microbix’s FQ1 2026 financial results. All of KRC’s previous research reports, including this latest one.
Microbix Reports Results for Q1 2026
Microbix reports results for its first quarter of fiscal 2026 ended December 31, 2025 (“Q1”). Results for Q1 demonstrated the Company’s efforts to rebuild revenue…
Microbix Welcomes The College of American Pathologists as a Client
Microbix is pleased to welcome the College of America Pathologists (“CAP”) as a customer for Microbix quality assessment products (“QAPs™”) for use in CAP clini…
Microbix Schedules Release of Results for Q1 Fiscal 2026
Microbix announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its first quarter of
fiscal 2026 en…
Microbix Presents Molecular Pathology Platform Results
Microbix announces that it is presenting results of its novel Quality Assessment Products (“QAPs™”) and platform technology for supporting the quality management an…
Microbix Updates Investor Presentation on its Website
Microbix announces that it has updated the investor presentation on its corporate website in response to comments of staff of the Ontario Securities Commission (OSC & OSC…
Microbix Commercializes SARS-CoV-2 (COVID) Recombinant Antigen
Microbix announces the commercial usage of its first recombinant antigen product, the nucleocapsid protein of the SARS-CoV-2 virus (COVID-19), in its quality assessment p…
Microbix Reports Results for Q4 and Fiscal 2025
Full-Year Revenues of $18.6 million and Net Loss of $2.2 million MISSISSAUGA, CANADA, December 18, 2025 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Schedules Release of Results for Q4 Fiscal 2025
Results Release and Webinar Discussion on Morning of December 18, 2025 MISSISSAUGA, CANADA, December 11, 2025 – Microbix Biosystems Inc. (TSX: MBX, OTCQX:…
Microbix Launches New Products to Support H3N2 Flu Testing
Test-Controls & Reference Materials for Labs & Test-Makers MISSISSAUGA, CANADA, December 10, 2025 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Announces Initiation of Normal Course Issuer Bid
For Repurchase of up to 5% of its outstanding shares over 12 months MISSISSAUGA, CANADA, December 4, 2025 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix & Seegene Mexico Collaborate to Improve Test Accuracy
announce that Microbix external third-party quality assessment products (QAPs®) will be used to support the clinical use of the Allplex™ and Anyplex™ molecular multi…
Microbix Partners with SEKISUI Diagnostics to Support COVID/Flu Tests
announce that Microbix external third-party quality assessment products (REDx™FLOQ® QAPs®) will be used to support SEKISUI’s U.S. commercialization of the molecular…
Microbix Presenting at Muskoka Capital Event
Microbix announces that it will be presenting to investors at the Muskoka Capital Event, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Ro…
Microbix Assisting EMQN with Second Genetic-Test EQA Program
and EMQN CIC (EMQN), a global supplier of laboratory external quality assessment (“EQA”) schemes for human genomic testing, announce the go-live of a program to suppo…
Microbix Hosts Ontario Minister Stephen Crawford
Microbix Biosystems announces its hosting of the Honourable Stephen Crawford, Ontario’s Minister of Public and Business Service Delivery and Procurement, for a site vis…
Microbix Reports Results for Q3 Fiscal 2025
Microbix Biosystems reports results for its third quarter and nine months of fiscal 2025 ended June 30, 2025 (“Q3” and “YTD”). Sales for Q3 were down for both An…
Microbix Schedules Release of Results for Q3 Fiscal 2025
Microbix Biosystems announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its third quarter of fisc…
Microbix Launches QUANTDx™ Characterized Reference Materials
Microbix Biosystems Inc. announces the commercial launch of QUANTDx™, a new product line of well-characterized reference materials designed to support the development a…
Microbix Exhibiting & Presenting at ADLM
Microbix Biosystems Inc. will be attending, exhibiting, and presenting at the Association for Diagnostic & Laboratory Medicine (“ADLM”) conference taking place in Chi…
Microbix & Bulgaria’s NCIPD Execute Supply Agreement
Microbix Biosystems Inc. and the National Center for Infectious and Parasitic Diseases of Bulgaria (“NCIPD”), announce an agreement whereby NCIPD will supply a portfo…
Microbix Attending & Presenting at Asia Pacific POC 2025
Microbix Biosystems Inc. announces that it is attending and presenting at the 2nd Asia Pacific Conference on Point of Care Testing for Infectious Diseases, taking place …
Imagine there’s no cervical cancer. It’s easy, if we try.
In Ontario, health expenditures now exceed $87 billion per year and comprise over 40 per cent of overall spending. Such expenses are growing faster than our per capita pr…
Microbix Reports Results for Q2 Fiscal 2025
Microbix reports results for its second quarter and first half of fiscal 2025 ended March 31, 2025 (“Q2” and “H1”). Sales for Q2 and H1 reflected differential gr…
Microbix & Aurevia Introduce Novel EQA Scheme
Microbix & Aurevia announce a pilot external quality assessment (“EQA”) program to help clinical laboratories establish their proficiency at using molecular diagnosti…
Microbix Schedules Release of Results for Q2 Fiscal 2025
Microbix announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its second quarter of fiscal 2025 en…
Microbix’s Clot-Buster Drug Project Advances
Microbix announces that its funding and commercialization partner, Sequel Pharma, LLC (“Sequel”), has executed an agreement with a leading international contract deve…
Microbix Presenting at the 2025 Bloom Burton Conference
announces it will be attending and presenting at the 2025 Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Conve…
Microbix Exhibiting at ESCMID Global 2025
announces that it will be attending and exhibiting at ESCMID Global 2025 and that a customer and collaborator will be presenting results of a pilot External Quality Asses…
Microbix Provides Business Updates
provides an update on U.S. and reciprocal tariff outcomes as well as business conditions and its outlook for the balance of its fiscal 2025.
Microbix Announces Annual and Special Meeting Voting Results
announces the voting results from the Annual and Special Meeting of Shareholders of the Company (the “Meeting”) which was held on March 26, 2025.
Microbix Further Optimizes Capital Usage and Availability
announces the further optimization of the structure and utilization of its capital via the repayment of mortgage debt and expansion of its bank line of credit – Moves t…
Microbix & ACPCC support efforts to eliminate cervical cancer in the Indo-Pacific
announce that they have signed a Memorandum Of Understanding (MOU) under which Microbix will supply its PROCEEDx™FLOQ® brand Quality Assessment Products (QAPs™) to s…
Microbix Hosts Ontario Premier Doug Ford & Team
was pleased to host Government of Ontario candidates Premier Doug Ford (Etobicoke North riding) and local MPP Deepak Anand (Mississauga-Malton riding). During their site …
Microbix Announces Issuance of Stock Options
announces the issuance of stock options under its shareholder-approved stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentiviz…
Microbix Presenting at Investor Conference in B.C.
announces that it will be presenting to equity investors at the Whistler Capital Event conference, organized by Capital Event Management Ltd. and being hosted at the Fair…
Microbix Reports Strong Revenues & Earnings for Q1 Fiscal 2025
reports results for its first quarter of fiscal 2025 ended December 31, 2024 (“Q1”).
Microbix Schedules Release of Results for Q1 Fiscal 2025
announces that it expects to file the financial statements and management disclosure and analysis for its first quarter of fiscal 2025 ended December 31, 2024 (“Q1 2025…
Microbix Receives $2.4 Million from Exercise of Warrants
announces that it has received C$ 2.4 million in new equity capital from the partial exercise of expiring share purchase warrants.
Microbix & API Ensuring Flu Tests Can Detect H5N1 Strain
Microbix and American Proficiency Institute (API), a groundbreaking supplier of proficiency testing (“PT”) to over 20,000 clinical laboratories, announce the start of…
Microbix Expanding Addressable Market Share with Test Makers
announces its intentions to broaden its platform capabilities to enable production of a wider range of test ingredients (“Antigens”) by using recombinant production t…
Microbix Reports Record Product Sales for Q4 and Fiscal 2024
reports results for its fiscal year and fourth quarter ended September 30, 2024 (“2024” and “Q4”) with record revenues, reflective of ongoing progress to increase…
Microbix Schedules Release of Results for Q4 Fiscal 2024
announces that it expects to file the financial statements and management disclosure and analysis for its fourth quarter of fiscal 2024 ended September 30, 2024 (“Q4 20…
Microbix Assisting EMQN with Novel Genetic-Test EQA Program
with EMQN announce the go-live of a program to support the accurate identification of patients who carry a gene-variant associated with increased susceptibility to hearin…
Microbix Announces Initiation of Normal Course Issuer Bid
announces the initiation of a Normal Course Issuer Bid (“NCIB”) program for the repurchase and cancellation of outstanding common shares.
KOL Collaborators Present Microbix HPV Test-Control Results
announces that key opinion leader (“KOL”) collaborators are presenting results of a Microbix Quality Assessment Product (“QAP™”) for controlling testing for hig…
Microbix Presents Novel HSV Test Control at EMMD
announces that it is presenting results of a novel Quality Assessment Product (“QAP™”) for supporting patient diagnosis and tissue analysis relating to infection wi…
Microbix Achieves Essential EU Regulatory Accreditations
Microbix announces that it has upgraded its European Union (“EU”) regulatory compliance for its diagnostic assay quality assessment products (“QAPs™”).
Microbix Presenting at Muskoka Capital Conference
Microbix will be presenting to investors at the Muskoka Capital Conference, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka…
Microbix Reports Continued Strong Results for Q3 Fiscal 2024
Microbix Biosystems Inc. reports results for its third quarter and first nine months of fiscal 2024 ended June 30, 2024 (“Q3” and “YTD”) with strong revenues, ref…
Microbix Schedules Release of Results for Q3 Fiscal 2024
Microbix Biosystems Inc. announces that it expects to file the financial statements and management disclosure and analysis for its third quarter of fiscal 2024 ended June…
Microbix Presents HCV FLOQSwab® Format Test Control at ADLM
Microbix Biosystems Inc. introduces a novel Quality Assessment Product (QAP™) for Hepatitis C Virus (HCV) POCTs at the ADLM conference. This swab-based, room-temperatur…
Microbix Hosts Minister Nina Tangri to Open Capacity Expansions
Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces its hosting of Associate Minister of Small Business of Ontario, the Honourable …
Microbix Advances Test-Ingredient Manufacturing Capabilities
Microbix is a global leader in the production of native Antigens – preparations of purified and inactivated bacteria and viruses essential for the manufacture of “imm…
Microbix Reports Strong Results for Q2 Fiscal 2024
Revenues of $5.6 million and Net Income of $0.4 million MISSISSAUGA, CANADA, May 15, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life…
Microbix Schedules Release of Results for Q2 Fiscal 2024
Results Release and Webinar Discussion on Morning of May 15, 2024 MISSISSAUGA, CANADA, May 8, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a…
Microbix Collaborator Introduces New Lab Accreditation Program
Microbix Product Supporting Testing for Drug-Resistant Sexually-Transmitted Infection MISSISSAUGA, CANADA, April 25, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX:…
Microbix Presenting at the 2024 Bloom Burton Conference
MISSISSAUGA, CANADA, April 11, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it…
Microbix Announces Annual and Special Meeting Voting Results
MISSISSAUGA, April 1, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF) (“Microbix®” or the Company”), a life sciences innovator and exporter, announces the…
Microbix’s Clot-Buster Drug Project Advances
Sequel Pharma Executes Agreement with CDMO for Drug Substance Production MISSISSAUGA, CANADA, March 14, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Unveils Test Controls for Head and Neck Cancer
HPV-related Tissue-Sample Mimics for QC of histology and PCR analyses MISSISSAUGA, CANADA, March 11, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Enhances Quality Management System
ISO 13485:2016 Medical Devices Certification Attained TORONTO, December 24, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological…
Microbix Announces Issuance of Stock Options
Using Shareholder-Approved Plan to Incentivize and Retain MISSISSAUGA, CANADA, February 26, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®),…
Microbix Reports Record Results for Q1 Fiscal 2024
Record Revenues of $8.4 million and Record Net Income of $2.5 million MISSISSAUGA, CANADA, February 14, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Schedules Release of Results for Q1 Fiscal 2024
Results Release and Webinar Discussion on Morning of February 14, 2024 MISSISSAUGA, CANADA, February 7, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Unveils Test Control for Gastric Ulcer Disease Pathogen
FLOQSwab-formatted QAP Supporting MDx Tests for H. pylori MISSISSAUGA, CANADA, February 6, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life…
Microbix Achieves Further QAPs Sales Record
Over C$ 1 Million in One Shipment to a Leading Lab Accreditation Agency MISSISSAUGA, CANADA, January 3, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Reports Results for Q4 & Full-Year Fiscal 2023
Full-Year Sales of $16.5 million and Net Loss of $0.04 million MISSISSAUGA, CANADA, December 21, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a…
Microbix & Seegene USA Jointly Enhancing Lab Test Accuracy
Expanded Collaboration to Improve Syndromic Infectious Disease Testing MISSISSAUGA, CANADA & IRVINE, CALIFORNIA, December 14, 2023 – Microbix Biosystems Inc. (TSX:…
Microbix & BioGX Collaborate on real-time PCR Assays & Controls
Quality Controls for Respiratory Viral, Pharyngitis, and Genital Ulcer Disease Panels MISSISSAUGA, CANADA & BIRMINGHAM, ALABAMA, December 7, 2023 – Microbix…
Microbix Announces Initiation of Normal Course Issuer Bid -2023
For Repurchase of up to 5% of its outstanding shares over 12 months MISSISSAUGA, CANADA, December 6, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Presenting at Florida Capital Event Conference
Meetings with Growth-Oriented Investors, November 17 to 19, 2023 MISSISSAUGA, CANADA, November 17, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Clot-Buster Drug Fully-Funded For Return to U.S. Market
Sequel Pharma Reconfirms Kinlytic® urokinase Support for Catheter Clearance Indication MISSISSAUGA, CANADA, November 16, 2023 – Microbix Biosystems Inc. (TSX: MBX,…
Microbix & Ulisse Biomed Collaborate on HPV Controls & Assays
Onboarding Tools and Quality Controls for Extended Genotype HPV Assays MISSISSAUGA, CANADA & TRIESTE, ITALY, November 10, 2023 – Microbix Biosystems Inc. (TSX: MBX,…
Microbix QAPs Supporting HPV Testing in Ireland
Distribution Partner Secures Contract Relating to Cervical Cancer Screening MISSISSAUGA, CANADA, October 27, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Presenting at Muskoka Capital Conference – 2023
Meetings with Growth-Oriented Investors, September 29 to October 1, 2023 MISSISSAUGA, CANADA, September 29, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX:…
Microbix Achieves New QAPs Sales Record
Over C$ 1 Million in Orders from Leading Diagnostics Industry Test-Maker MISSISSAUGA, CANADA, September 27, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Honours the Passing of its Founder William J. Gastle – 1948 to 2023
Microbix Honours the Passing of its Founder William J. Gastle – 1948 to 2023 MISSISSAUGA, CANADA, September 13, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Reports Results for Q3 Fiscal 2023
Strong Sales of $5.5 million alongside Drug Partnering Agreement MISSISSAUGA, August 10, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a…
Microbix Successfully Upgrades Logistics Software Systems
Achieves “Go-Live” with New ERP and eQMS Solutions MISSISSAUGA, CANADA, August 4, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences…
Microbix Presents Results of STI Test Controls at AACC
FLOQSwab-formatted QAPs Supporting Fourplex PCR Tests for Bacterial STIs MISSISSAUGA, CANADA, July 24, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix QAPs Supporting HPV Testing Across The Netherlands
Distribution Partner Secures Contract Relating to Cervical Cancer Screening MISSISSAUGA, CANADA, July 5, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix & Labquality Create Novel Testing Accreditation Program
Innovative “EQA” Program to Qualify Labs for Genital Ulcer Disease Testing MISSISSAUGA, CANADA & HELSINKI, FINLAND – June 20, 2023 – Microbix Biosystems Inc. (TSX:…
Microbix Presents Results of STI Test Controls at ASM Microbe
FLOQSwab-formatted QAPs supporting PCR Tests for Antibiotic-Resistant Pathogens MISSISSAUGA, CANADA, June 13, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Announces Extension of Warrant Expiry Date
Applies for 12-month Term Extension of May 2021 Warrants MISSISSAUGA, CANADA, May 18, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life…
Microbix Secures Funded Drug Commercialization Agreement
Kinlytic® urokinase to be developed for re-entry into U.S. market MISSISSAUGA, CANADA, May 16, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a…
Microbix Reports Results for Q2 Fiscal 2023
Sales of $4.2 million and Profitability MISSISSAUGA, May 11, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator,…
Microbix Presenting at the 2023 Bloom Burton Conference
MISSISSAUGA, CANADA, April 20, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it…
Microbix Announces Annual and Special Meeting Voting Results – March 30, 2023
MISSISSAUGA, March 30, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF)( “Microbix®” or the Company”), a life sciences innovator, manufacturer, and exporter,…
Microbix Annual General Meeting (AGM) Update
Remote Access to the AGM Provided to Avoid Physical Attendance MISSISSAUGA, CANADA, March 22, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a…
Governments of Ontario and Canada Invest in Microbix
$ 1.68 Million in Funding for Capabilities and Capacity Expansions MISSISSAUGA, CANADA, March 20, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a…
Microbix Supporting Australian Point-of-Care Testing Program
QAPs used in Diagnostic Testing for STIs in Remote Communities MISSISSAUGA, CANADA, March 1, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life…
Microbix Announces Issuance of Stock Options – Feb 27th 2023
Using Shareholder-Approved Plan to Incentivize and Retain MISSISSAUGA, CANADA, February 27, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life…
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million
Sales of $2.5 million, Net Loss of $1.3 million MISSISSAUGA, February 9, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences…
Microbix Presenting Results of Collaboration with Health PEI
QAPs for HPV Test Verification within Cervical Cancer Screening Program MISSISSAUGA, CANADA, February 6, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Launches QAP to Support “Monkeypox” Testing
Driven by Customer Requests, Mpox Test Control Now Available MISSISSAUGA, CANADA, January 30, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a…
Microbix Reports Record Sales for Fiscal 2022
Record Sales of $19.1 million, Net Earnings of $1.8 million MISSISSAUGA, December 22, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life…
Microbix Presenting Test-Workflow Validation Results at EMMD
MSwab® & PROCEEDx™FLOQ® Supporting Self-Collection for HPV Screening Programs MISSISSAUGA, CANADA, October 6, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX:…
Microbix Announces Initiation of Normal Course Issuer Bid – 2022
Microbix to Repurchase up to 5% of its outstanding shares over 12 months MISSISSAUGA, CANADA, September 28, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Presenting at Muskoka Capital Conference – Meetings with Growth-Oriented Investors, September 23-25, 2022
Meetings with Growth-Oriented Investors, September 23-25, 2022 MISSISSAUGA, CANADA, September 21, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Reports Results for Q3 Fiscal 2022
Q3 Sales of $5.0 million, Q3 Net Earnings of $0.6 million MISSISSAUGA, August 11, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life…
Microbix Executes Substantial QAPs Supply Agreement
Microbix QAPs to Support Molecular & Antigen Test Platforms for Multiple Diseases MISSISSAUGA, CANADA, August 10, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX:…
Microbix Presenting STI Multiplex Test Controls at AACC
Quality Control Materials for Genital Ulcer Disease Molecular Assays MISSISSAUGA, CANADA, July 26, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®),…
Microbix Presenting Test Validation Methods at AACC
Usage of QAPs to Validate Whole Workflow Quality Control of Testing MISSISSAUGA, CANADA, June 3, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a…
Microbix Reports Record Results for Q2 Fiscal 2022
Record Q2 Sales of $4.9 million, Q2 Net Earnings of $0.7 million MISSISSAUGA, May 12, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life…
Microbix Presenting Omicron Test Control Results at CVS
QAPs Supporting Molecular Diagnostic Tests for Dominant COVID-variant MISSISSAUGA, CANADA, April 29, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Presenting at the 2022 Bloom Burton Conference
Healthcare Investor Conference in Toronto on May 2 & 3, 2022 MISSISSAUGA, CANADA, April 28, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a…
Microbix Presenting Respiratory Virus Controls Data at Two Events
QAPs Supporting Tests That Simultaneously Detect Multiple Respiratory Viruses MISSISSAUGA, CANADA, April 19, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Presenting HPV Product Results at EUROGIN
QAPs Supporting Screening-Tests for High-Risk Human Papilloma Viruses MISSISSAUGA, CANADA, April 8, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®),…
Microbix Announces Annual and Special Meeting Voting Results – March 31, 2022
Microbix Announces Annual and Special Meeting Voting Results MISSISSAUGA, CANADA, March 31, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a…
Microbix Invests to Further Scale Its Business
Implementing MasterControl® and NetSuite® Solutions to Enable Rapid Growth MISSISSAUGA, CANADA, March 29, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Announces Issuance of Stock Options – Feb 22nd 2022
Using Shareholder-Approved Plan to Incentivize and Retain MISSISSAUGA, CANADA, February 24, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a…
Microbix Announces Nomination to Board of Directors
For Appointment of Jennifer Stewart, Accomplished Business Leader MISSISSAUGA, CANADA, February 22, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®),…
Microbix Presenting at Capital Conference in B.C.
Meetings with Growth-Oriented Investors, February 18-20, 2022 MISSISSAUGA, CANADA, February 17, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Advances Commissioning of Sites Two and Three
Expansion of Capacity for Manufacturing of QAPs & DxTM MISSISSAUGA, CANADA, February 15, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life…
Microbix Reports Record Results for Q1 Fiscal 2022
Record Q1 Sales of $4.9 million, Record Q1 Net Earnings of $0.9 million MISSISSAUGA, February 10, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Launches Omicron Variant Test Control
Helping Ensure Workflow Accuracy of Tests for Respiratory Viruses MISSISSAUGA, CANADA, February 1, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®),…
Microbix Receives $4.7 Million Order for Viral Transport Medium
Follow-on Order from Government of Ontario Procurement Authorities MISSISSAUGA, CANADA, December 24, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Reports Record Results for Fiscal 2021
Record Sales of $18.6 million, Record Net Earnings of $3.2 million MISSISSAUGA, December 23, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®),…
Microbix Launches Multiplex Respiratory PCR-Test Control
Helping Ensure Workflow Accuracy of Tests for COVID, Flu A, Flu B, and RSV MISSISSAUGA, CANADA, December 20, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Expands Pandemic Test Controls (QAPs™) Portfolio
Helping Ensure Workflow Accuracy of PCR Tests for COVID “Variants of Concern” MISSISSAUGA, CANADA, November 17, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,…
Microbix Receives $2.7 Million from Exercise of Warrants
Further Capital to Assist with Increasing Capacity and Efficiency MISSISSAUGA, CANADA, October 27, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®),…
Microbix Makes Early Repayment of 9% Interest Debenture
$1.3 million balance repaid, improving cash flow and resulting in non-cash charge MISSISSAUGA, CANADA, October 4, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX:…
Microbix Presenting Product Results at AACC – QAPs to Support Testing for COVID Viral Variants
QAPs to Support Testing for COVID Viral Variants MISSISSAUGA, CANADA, September 27, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences…
Microbix Reports Record Results for Q3 Fiscal 2021
Record Sales of $5.5 million, Record Net Earnings of $1.5 million MISSISSAUGA, August 12, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a…
Microbix Upgrades U.S. OTC Market & Investor Relations
Trading Upgrade to OTCQX Best Market and Torrey Hills Capital Engaged MISSISSAUGA, ON, August 3, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a…
Microbix Presenting Product Results to Industry
Two Abstracts Reporting on Cross-Platform Utility of Antigen & Serological QAPs™ MISSISSAUGA, CANADA, July 8, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB:…
Microbix Announces Quality Products Distribution Agreement – Appointment of Thomas Scientific as U.S. Distributor
Appointment of Thomas Scientific as U.S. Distributor MISSISSAUGA, July 7, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator…
Microbix Secures Third Ontario Manufacturing Site
Leasing and Equipping 10,000 Square Foot Building Adjacent to Current Sites MISSISSAUGA, June 3, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a…
Microbix Announces Quality Products Distribution Agreement – Appointment of SDT Molecular of Singapore
Appointment of SDT Molecular of Singapore MISSISSAUGA, May 31, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and…
Microbix Announces Closing of Offering and Private Placement
$6.9 Million of Gross Proceeds Received – NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES – MISSISSAUGA, May 19, 2021 – Microbix Biosystems…
Microbix Reports Record Results for Q2 Fiscal 2021
Record Q2 Sales of $4.35 million, Record Net Earnings of $0.8 million MISSISSAUGA, May 13, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life…
Microbix Announces $6.0 Million of Financings
$5.0 Million Bought-Deal Public Offering and $1.0 Million Private Placement – NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES –…
Microbix & SpeeDx Form Exclusive Collaboration
Focus on Diagnostics and Controls for Anti-Microbial Resistant Infections MISSISSAUGA, CANADA and EVELEIGH, AUSTRALIA April 26, 2021 – Microbix Biosystems Inc. (TSX:…
Microbix Receives $4.25 Million Order For Viral Transport Medium
An Initial Order From Government Of Ontario Procurement Authorities MISSISSAUGA, April 23, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life…
Microbix Announces Annual and Special Meeting Voting Results – March 31, 2021
MISSISSAUGA, March 31, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF)( “Microbix®” or the Company”), a life sciences innovator and exporter, announces the…
Microbix & Seegene Canada Form COVID-Variant Collaboration
Focus on Supporting Canadian Labs with Variant-related Assays and QAPs MISSISSAUGA & TORONTO, March 15, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF,…
Microbix Antigen-test QAPs Now Available For Clinical Use
REDxFLOQ SARS-CoV-2 Antigen as IVD Controls in Canada, the EU, and the U.S. MISSISSAUGA, March 11, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®),…
Microbix Announces Issuance of Stock Options – Feb 18th 2021
Using Shareholder-Approved Plan to Incentivize and Retain MISSISSAUGA, February 18, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences…
Microbix Announces Quality Products Distribution Agreement – Oneworld Accuracy as a Non-Exclusive Distributor for Africa and Other Territories
Oneworld Accuracy as a Non-Exclusive Distributor for Africa and Other Territories MISSISSAUGA, February 16, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF,…
Microbix Reports Results for Q1 Fiscal 2021
Record Q1 Sales, With Nearly 3,600% Year-Over-Year QAPs Growth MISSISSAUGA, February 11, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a…
Microbix Announces Material First Sales of Viral Transport Medium
Initial Production of 50,000 Vials Entirely Sold MISSISSAUGA, February 9, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator…
Microbix Viral Transport Medium Now Available
Initial Capacity of 50,000 Vials/Week under Health Canada Regulation MISSISSAUGA, January 28, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a…
Microbix & Copan Italia Execute Strategic Agreement
For FLOQ devices & QAPs Co-branding, IP licensing, Co-marketing, Purchase, and Supply MISSISSAUGA, CANADA and BRESCIA, ITALY, December 21, 2020 – Microbix…
Microbix Reports Results for Fiscal 2020
Full-Year Sales of $10.5 Million, QAPs Sales Grow by 41% MISSISSAUGA, December 18, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator…
Microbix Presenting Product Results at AACC – Reporting on Test-Workflow Controls for Important Sexually-Transmitted Infections
Reporting on Test-Workflow Controls for Important Sexually-Transmitted Infections MISSISSAUGA, CANADA, December 15, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB:…
Microbix Announces Addition to Board of Directors
Appointment of Anthony J. Giovinazzo, Accomplished Life Sciences Leader MISSISSAUGA, CANADA, December 7, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF,…
Microbix Discloses New Products, Sales, And Capacity
Sales Of QAPs™ Kits To Help Qualify Multi-Pathogen Respiratory Test Systems MISSISSAUGA, CANADA, October 29, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB:…
Microbix Creates Further COVID-19 Quality Assessment Products
QAPs™ To Support Accuracy Of COVID-19 Antigen-Test Workflows MISSISSAUGA, CANADA, October 20, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®),…
Ontario Helps Microbix Ensure Provincial COVID Testing Capacity
Grant Of $1.45 Million For Ontario-Based Production Of Critical Test Reagents MISSISSAUGA, October 13, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF,…
Microbix Presenting COVID-19 Product Results To Industry
Abstract Reports Multi-Platform Utility Of IVD SARS CoV-2 Lab Workflow Control MISSISSAUGA, CANADA, September 22, 2020 – Microbix Biosystems Inc. (TSX: MBX,…
Microbix Announces Extension Of Warrant Expiry Dates
Applies For 12-Month Term Extension Of October 2015 And October 2017 Warrants MISSISSAUGA, CANADA, September 17, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB:…
Microbix Announces Board Changes
William J. Gastle Retiring, Martin Marino Nominated To Become Independent Chairman MISSISSAUGA, CANADA, September 15, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB:…
Microbix’s REDx™ Controls Attain Australian TGA Registration
Enables Use of COVID-19 and HPV Products by Australian Clinical Labs MISSISSAUGA, CANADA, September 10, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF,…
Q3 Fiscal 2020
Year-Over-Year QAPs Sales Growth of 141% for Q3 MISSISSAUGA, August 14, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator…
Microbix Shares Become Available For U.S. Investors
OTC Markets Listing and DTC Electronic Clearance Eligibility MISSISSAUGA, ON, CANADA, July 14, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), an…
Microbix COVID-19 QAPs Attain EU “CE Mark” Registration
Enables Usage of SARS-CoV-2 Controls by Clinical Labs across Europe MISSISSAUGA, CANADA, June 5, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning…
Microbix Announces Quality Products Distribution Agreement – Appointment of Medical Supply Company of Ireland
Appointment of Medical Supply Company of Ireland MISSISSAUGA, March 24, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making…
Microbix Engaged To Develop & Supply Custom QAPs™
Instrument-Specific Controls to Support Rapid Tests for Viral Respiratory Pathogens MISSISSAUGA, June 1, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an…
Microbix Expanding QAPs™ Production Capacity
Build-out to Support Tenfold Increase Now Underway MISSISSAUGA, CANADA, May 27, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences…
Microbix Achieves Full Utilization Of Its Bioreactors
Six Units in Ongoing Use for Foreseeable Future, Seventh Ordered MISSISSAUGA, CANADA, May 19, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning…
Microbix Announces Quality Products Distribution Agreement – Appointment of Labquality Oy of Finland for 7 Countries
Appointment of Labquality Oy of Finland for 7 Countries MISSISSAUGA, April 27, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences…
Microbix Reports Record Second Quarter Sales – Year-Over-Year Sales Growth of 28% in First-Half
Year-Over-Year Sales Growth of 28% in First-Half TORONTO, May 14, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and…
Microbix Reports Results For Q2 Fiscal 2020
Timing of Product Shipments Affects Results MISSISSAUGA, May 14, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and…
Microbix Announces Quality Products Distribution Agreement – Appointment of D.I.D. S.p.A. of Milan for Italy
Appointment of D.I.D. S.p.A. of Milan for Italy MISSISSAUGA, May 12, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and…
Microbix COVID-19 QAPs Now Available for U.S. Labs
Registration Enables Immediate Usage of SARS-CoV-2 Controls by U.S. Clinical Labs MISSISSAUGA, CANADA, May 7, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an…
Microbix Begins Providing COVID-19 Test Quality Products
SARS-CoV-2 Controls for Canadian Labs in Swab and Vial Formats MISSISSAUGA, CANADA, May 6, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life…
Microbix Announces Quality Products Distribution Agreement – Appointment of R-Biopharm AG for 11 Countries
Appointment of R-Biopharm AG for 11 Countries MISSISSAUGA, May 15, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and…
Microbix Attains Health Canada Establishment Licensing
Enables Immediate Usage of SARS-CoV-2 Controls by Clinical Labs across Canada MISSISSAUGA, CANADA, April 21, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), a…
Microbix & Oneworld Create COVID-19 Test Quality Program
Laboratory External Quality Assessment, Proficiency Testing, & Accreditation MISSISSAUGA, ONTARIO and VANCOUVER, BC, CANADA, April 9, 2020 – Microbix Biosystems…
Microbix Announces Annual And Special Meeting Voting Results – April 2, 2018
TORONTO, April 2, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces the voting results from the…
Microbix Creates Quality Assessment Product For COVID-19 Tests
Whole-genome QMS Support Tool on COPAN® FLOQSwabs® MISSISSAUGA, CANADA, March 30, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®) announces the creation,…
Microbix Annual General Meeting Process Update
Remote Access to the AGM Provided to Avoid Physical Attendance MISSISSAUGA, March 25, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator…
Microbix Announces Quality Products Distribution Agreement – Appointment of Alpha-Tec Systems, Inc. for the United States
Appointment of Alpha-Tec Systems, Inc. for the United States MISSISSAUGA, June 4, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences…
Microbix Announces Issuance Of Stock Options – Sep 13th 2017
Customer Validation of New Manufacturing Process Completed TORONTO: September 13, 2017 – Microbix Biosystems Inc. (TSX: MBX), a developer and marketer of biological…
Microbix Reports Results For Q1 Fiscal 2020
Positive Cash Flow from Operations Achieved MISSISSAUGA, February 13, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical…
Microbix Completes Non-Brokered Private Placement Of $2.3 Million
TORONTO, October 19, 2017 – Microbix Biosystems Inc. (TSX: MBX) (“Microbix” or the “Company”), a developer and marketer of biological products and technologies,…
Microbix Reports Results For Fiscal 2019
Full-Year Sales of $13.4 Million, Progress Toward Sustained Profitability MISSISSAUGA, December 20, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life…
Microbix Wins Ontario Business Award
2019 “OBAA” for Excellence in Export Strategy MISSISSAUGA, November 18, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making…
Microbix Quality Products Enter U.S. Market
Four IVD Controls to Support Performance of Human Papilloma Virus (HPV) Tests MISSISSAUGA, September 19, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an…
Microbix Quality Products Attain European Registration
Four IVD Controls to Support Performance of Human Papilloma Virus (HPV) Tests MISSISSAUGA, September 5, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an…
Microbix Reports Results For Q3 Fiscal 2019
Q3 Sales of $3.1 Million and $9.8 Million Year-To-Date TORONTO, August 12, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products…
Microbix Provides Bioreactor Update
Largest Customer Confirms Conversion Timetable & Provides Full-Scale Order TORONTO, August 1, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an…
FedDev Ontario Supports New Microbix Facility In Mississauga
Contribution of $2.75 Million to Scale-up, Meet Demand, and Create Highly-Skilled Jobs MISSISSAUGA, July 30, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an…
Microbix Reports Results For Q2 Fiscal 2019
Record Sales of $4.25 Million, Sales Growth of 42%, and Material Net Earnings TORONTO, May 13, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of…
Microbix Announces Management Changes
Ken Hughes Appointed COO, Kathryn Froh Retiring TORONTO, April 18, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and…
Microbix Announces Annual Meeting Voting Results – March 28, 2019
TORONTO, March 28, 2019 – Microbix Biosystems Inc. (TSX: MBX, “Microbix” or the “Company”), an innovator of biological products and technol…
Microbix Announces Issuance Of Stock Options – Feb 25th 2020
Using Shareholder-Approved Plan to Incentivize and Retain TORONTO, February 25, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making…
Microbix Reports Results For Q1 Fiscal 2019
Lower Sales, Improving Gross Margin, Positive Cash Flow from Operations TORONTO, February 12, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of…
Microbix Provides Quality Assessment Products Update
New Customers, More Products, and Expanding Capacity TORONTO, February 5, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological…
Microbix Enhances Quality Management System
ISO 13485:2016 Medical Devices Certification Attained TORONTO, December 24, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological…
Microbix Reports Results For Fiscal 2018
Full-Year Sales Growth of 23%, Progress Toward Sustained Profitability TORONTO, December 21, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of…
Microbix Wins Business Award Of Excellence
Recognized with 2018 Business Innovation Award by MBOT TORONTO, November 19, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological…
Microbix Reports Record Third Quarter Sales
Microbix Reports Record Third Quarter Sales Year-Over-Year Sales Growth of 24% in First Nine Months TORONTO, August 14, 2018 – Microbix Biosystems Inc. (TSX:…
Microbix Reports Record Second Quarter Sales
Microbix Reports Record Second Quarter Sales
Microbix Completes Multiple Facility Upgrades
Production Capacity Increased to Support Growth Objectives TORONTO, May 8, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological…
Microbix Engages Drug Licensing Advisor
Torreya Partners to Assist with Kinlytic® urokinase TORONTO, April 26, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products…
Microbix Announces Annual And Special Meeting Voting Results – , April 2, 2018
TORONTO, April 2, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces th…
Microbix Reports Record First Quarter Sales – Year-Over-Year Sales Growth Of 48%
TORONTO, February 14, 2018 ‐ Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports financial results for its…
Microbix Expands Quality Assessment Product Family
48 New Products Being Added, Under PTDx™ and PROCEEDx™ Brands TORONTO, January 18, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of…
Microbix Reports Full Year And Fourth Quarter Results – Record Sales Of $10.2 Million Achieved For Fiscal 2017
TORONTO, December 21, 2017 – Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, reports financial results for its fiscal year…
Microbix Confirms Ramp-Up Of Production – Bioreactor Capacity Increasing By 500%
TORONTO, November 27, 2017 – Microbix Biosystems Inc. (TSX: MBX), a developer and marketer of biological products and technologies, confirms its production ramp-up,…
Microbix Completes Second Tranche Of Brokered Private Placement Tranche Gross Proceeds Of $1,164,640, Total Proceeds Of $3,500,000
TORONTO, October 27, 2017 – Microbix Biosystems Inc. (TSX: MBX) (“Microbix” or the “Company”), a developer and marketer of biological products and technologies,…
Microbix Completes Brokered Private Placement – Gross Proceeds Of $2.3 Million
TORONTO, October 19, 2017 – Microbix Biosystems Inc. (TSX: MBX) (“Microbix” or the “Company”), a developer and marketer of biological products and technologies,…
Microbix Announces End Of Legal Dispute – Allegations By ZeptoMetrix Withdrawn
OCTOBER 11, 2017 TORONTO, October 11, 2017 – Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, is pleased to announce the…
Microbix Announces First Shipment Of Bioreactor Antigen
Customer Validation Of New Manufacturing Process Completed TORONTO: September 13, 2017 – Microbix Biosystems Inc. (TSX: MBX), a developer and marketer of biological…
Microbix To Amend Share Purchase Warrant Terms
TORONTO August 24 2017 – Microbix Biosystems Inc. (TSX: MBX), a developer and marketer of biological products and technologies, announces it has applied to the TSX to…
Microbix Reports Record Third Quarter & Nine Month Sales – Year-Over-Year Sales Growth Exceeding 20%
TORONTO, August 14, 2017 – Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, today reports financial results for its fiscal…
